Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Intelligent Systems (INS) -- Ignore unavailable to you. Want to Upgrade?

To: architect* who wrote (5)	3/13/2000 12:33:00 AM
From: architect*	Read Replies (1) \| Respond to of 25

INTELLIGENT SYSTEMS, INVESTMENT HOLDINGS 155.229.195.82 INS is a MAJORITY OWNER in these private companies ChemFree, (INS majority owner) Industrial parts cleaning chemfree.com QS Technologies, Inc, (INS majority owner) Software solutions for Public Health qsinc.com Rapha, (INS majority owner) raphacare.com INS is a PARTIAL OWNER in these private companies, % ownership listed PaySys International, ( INS owns 28%) Dominates the market as the leader in banking and retail/private label credit card systems. paysys.com Digital Wireless, (INS owns 21%) design, manufacture, and marketing of wireless communication devices digital-wireless.com Visibility, (INS owns 33% ) a software company that markets engineer-to-order software. visibility.com Risk Labs, (INS owns 29%) markets risk management software risklabs.com INS ownership in PUBLIC COMPANIES # shares listed INS owns 66,431 shares of Primus stock NASDAQ : PKSI $130 per share X 66,431 shares = $8.6 Million INS owns 10,000 shares of S1 NASDAQ : SONE $105 per share x 10,000 shares = $1.05 Million INS sold Media Metrix - ISC was an early investor in the predecessor of Media Metrix, an Internet usage measurement and analysis company. MMXI went public in May of 1999 and INS sold it's 24,500 shares in November 1999. Value of sale 24,500 x $50 share = $1.22 Million INS is an INVESTOR in these private companies The percentage ownership is not listed on these companies on the INS website. Novient - novient.com INS is an investor in Novient, a company involved in web-based professional services automation solutions. Atherogenics - 155.229.195.82 INS is a co-investor with Alliance Technology Ventures, Sprout Group and Domain Partners, among others, in Atherogenics, a development stage company involved with novel pharmaceuticals and diagnostic markers which address cardiovascular disease and its intervention. TransNexus - transnexus.com INS is a partner in TransNexus, an early stage company developing a settlement and clearinghouse service for voice over IP. Medizeus - medizeus.com INS is the first investor in start-up Internet company, Medizeus. The company provides web-based diagnostic and reporting tools for radiologists, medical image archival services, and a women's health website, all of which are focused initially on the mammography market. MarketRing.com 155.229.195.82 INS is an early investor in MarketRing, a start-up Internet company. MarketRing.com provides Internet strategy and "infomediary" services to a broad array of vertical markets and industries, utilizing a proprietary WebRing model. ThinkWorks INS is the first outside investor in ThinkWorks, Inc., an early stage company that provides web-based recruitment automation and employee management automation tools via an application service provider model. MedicalJobsSource.com INS is an early investor in MedicalJobsSource.com which provides a comprehensive database for healthcare jobs and resumes. The company intends to be the premier source where healthcare professionals and organizations find each other. Commetrex Corporation INS was an early investor in Commetrex, a former incubator company, that develops and markets hardware and software products that enable communication systems providers to integrate multiline fax, data, video and voice. Discovery Therapeutics INS is a small investor, along with Alliance Technologies and Sanderling Ventures, among others, in Discovery Therapeutics. Discovery is developing new therapeutic products (at various stages of human trials) to treat cardio-renal diseases.